Piper Sandler analyst David Amsellem upgraded Intra-Cellular to Overweight from Neutral with a price target of $92, up from $68.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
- Intra-Cellular price target raised to $81 from $79 at JPMorgan
- Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
- Intra-Cellular price target raised to $130 from $120 at Cantor Fitzgerald
- Intra-Cellular price target lowered to $74 from $77 at Goldman Sachs